Abstract
Introduction
Sacituzumab govitecan is approved for the treatment of triple-negative advanced/metastatic breast cancer and hormone-receptor positive, HER2-negative advanced/metastatic breast cancer. Clinical trials show favorable improvements in progression-free survival (PFS) and overall survival (OS). However, they report a large percentage of patients experiencing hypersensitivity reactions. It has been observed that use of sacituzumab govitecan at [redacted institution] may have a lower rate of hypersensitivity reactions than seen in clinical trials.
Methods
This study aimed to determine the real-world data of PFS and OS of sacituzumab govitecan while evaluating the incidence and severity of hypersensitivity reactions. It was a retrospective, single-center, multi-site study conducted across [redacted], which included adult patients who received at least one dose of sacituzumab govitecan from April 1, 2020 to July 31, 2024 for an FDA-approved breast cancer indication.
Results
A total of 75 patients met the inclusion criteria for assessment. The median PFS was 2.8 months (95% CI, 0.0–14.4) and the median OS was 7.2 months (95% CI, 0.0–19.3). No hypersensitivity reactions were reported, hence reaction severity was not assessed nor associated with treatment discontinuation.
Conclusion and Relevance
This study demonstrated that PFS and OS may be shorter than estimated in clinical trials. However, baseline performance status and previous lines of therapy were not evaluated and thus may have impacted the results. Additionally, no hypersensitivity reactions were observed. From review of this data, the low risk of reactions helps justify future research to assess the necessity of certain premedications and/or elimination of observation times.
Keywords
Get full access to this article
View all access options for this article.